Who are Lidoderm 5% patch's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Proparacaine Ophthalmic, EXPAREL and bupivacaine HCl, Exparel Injectable Solution, Exparel Injectable Product, Epidural analgesia Ropivacaine, Lidocaine 1%/Epi 1:200000.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lidoderm-5-patch.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lidoderm 5% patch — Competitive Intelligence Brief

Lidoderm 5% patch (Lidoderm 5% patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management / Neurology.

marketed Local anesthetic Voltage-gated sodium channels Pain management / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Lidoderm 5% patch (Lidoderm 5% patch) — Nicole K Brogden. Lidocaine delivered transdermally blocks sodium channels in nerve fibers to provide localized pain relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lidoderm 5% patch TARGET	Lidoderm 5% patch	Nicole K Brogden	marketed	Local anesthetic	Voltage-gated sodium channels
Proparacaine Ophthalmic	Proparacaine Ophthalmic	American Genomics, LLC	marketed	Local anesthetic (ester)	Voltage-gated sodium channels
EXPAREL and bupivacaine HCl	EXPAREL and bupivacaine HCl	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Exparel Injectable Solution	Exparel Injectable Solution	The Cooper Health System	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Exparel Injectable Product	Exparel Injectable Product	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Epidural analgesia Ropivacaine	Epidural analgesia Ropivacaine	Universitair Ziekenhuis Brussel	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Lidocaine 1%/Epi 1:200000	Lidocaine 1%/Epi 1:200000	Wahba bakhet	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

University of California, San Diego · 3 drugs in this class
Durect · 3 drugs in this class
Pacira Pharmaceuticals, Inc · 3 drugs in this class
Wake Forest University Health Sciences · 3 drugs in this class
Medical University of Vienna · 3 drugs in this class
Imperial College London · 2 drugs in this class
Hvidovre University Hospital · 2 drugs in this class
Innocoll · 2 drugs in this class
George Washington University · 2 drugs in this class
Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lidoderm 5% patch — Competitive Intelligence Brief. https://druglandscape.com/ci/lidoderm-5-patch. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab